FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 349:815 August 21, 2003 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article Related Article by Earley, C. J. PubMed Citation

To the Editor: The Clinical Practice article by Earley on the restless legs syndrome (May 22 issue)¹ does not mention medications that are not used in the United States but are relevant to readers in other countries. In the section on dopamine agonists, there is no mention of the use of cabergoline, which has been shown to be effective in open-label and double-blind trials and is used fairly commonly for the treatment of the restless legs syndrome in Europe.^2,3 In our view, the long half-life of cabergoline makes it a particularly useful drug in terms of rebound and the augmentation . . . [Full Text of this Article]

Related Letters:

Enfuvirtide for Prophylaxis against HIV Infection
Cuzin L., Alvarez M., Ferranti S., Menichetti F.
Extract | Full Text | PDF  
N Engl J Med 2003; 349:2169-2170, Nov 27, 2003. Correspondence

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.